New research reveals that individuals who come off new slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional diet and exercise regimens.
Research printed in a major health publication points out that while overweight individuals often shed about a fifth of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these treatments should be informed of the danger of quick weight regain when the medication ends," warns researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment mass in about a year and a half.
Analyzing Approaches
The research, which reviewed 37 of trials involving thousands of participants, contrasted the effects of the injectable medications with conventional dieting.
Researchers note that individuals who shed pounds through dieting usually see a less rapid creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Rapid Regain
Experts believe the way of the drugs accounts for the amplified regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the system to produce less of its own natural hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS suggest the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts argue that, considering the high risk of relapse, the therapy is often ongoing.
This opinion is echoed by drug manufacturers, who say that the results "underscore the chronic nature of excess weight," akin to managing diseases like diabetes.
User Experiences
People who have stopped the jabs report a sudden return of cravings.
"It was like a switch flipping and I was suddenly ravenous," described an individual.
This difficulty is worsened if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Significant Interest
Recent estimates show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, clinicians caution that while the jabs are potent agents for weight loss, they are not a standalone fix and lasting health benefits hinges on combined lifestyle support.